ONGA
TVTX icon

O'Neil Global Advisors’s Travere Therapeutics TVTX Stock Holding History

O'Neil Global Advisors’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-51,191
Closed -$1.96M – 48
2025
Q4 		$1.96M Buy
+51,191
New +$1.66M 0.67% 23

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

O'Neil Global Advisors's TVTX Position: Q1 2026 in Review

O'Neil Global Advisors sold out of Travere Therapeutics (TVTX) in Q1 2026, closing a stake of 51,191 shares — an estimated $1.96M sold.

O'Neil Global Advisors first reported a position in TVTX in Q4 2025 and held it in 1 quarter. The position peaked at $1.96M in Q4 2025. 261 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • O'Neil Global Advisors reported no remaining Travere Therapeutics position as of Q1 2026 after selling out during the quarter.
  • O'Neil Global Advisors sold 51,191 Travere Therapeutics shares in Q1 2026, an estimated $1.96M.
  • O'Neil Global Advisors first reported a position in Travere Therapeutics in Q4 2025 and held it in 1 quarter.
  • O'Neil Global Advisors's Travere Therapeutics position peaked at $1.96M in Q4 2025.
  • 261 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on O'Neil Global Advisors's 13F filing for Q1 2026, filed 11 May 2026.